Results 61 to 70 of about 21,053 (285)

Edoxaban use in the context of dental procedures: analysis from the EMIT-AF/VTE database

BDJ Open, 2023
Introduction Literature reviews support continuing anticoagulation during dental procedures. However, studies often present grouped anticoagulation data, and information on individual anticoagulant management would be helpful to dentists.
Cathy Chen, Manish Saxena, Christian von Heymann, Thomas Vanassche, James Jin, Robert Lersch, Sabine Köhler, Amparo Santamaria, Martin Unverdorben, Paolo Colonna   +9 more
doaj   +1 more source

Teendők súlyos vérzés vagy sürgős sebészeti beavatkozás esetén direkt orális antikoaguláns gyógyszerrel kezeltekben. Az új dabigatran-antidótum: idarucizumab helye a klinikai gyakorlatban [PDF]

, 2016
Absztrakt Az elmúlt hat évtizedben csak a K-vitamin-antagonista kumarinokat alkalmazhattuk orális antikoagulánsként.
Boda, Zoltán
core   +1 more source

Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program

Journal of Clinical Medicine, 2023
Non-recommended dosing occurs in ~25–50% of non-vitamin K antagonist oral anticoagulant prescriptions, with limited data for edoxaban. We analyzed edoxaban dosing patterns in atrial fibrillation patients from the Global ETNA-AF program, relating patterns
T. Chao, M. Unverdorben, P. Kirchhof, Y. Koretsune, T. Yamashita, Robert A. Crozier, L. Pecen, Cathy Chen, A. Borrow, R. de Caterina   +9 more
semanticscholar   +1 more source

State of play and future direction with NOACs: An expert consensus. [PDF]

, 2018
Atrial fibrillation (AF) and venous thromboembolism (VTE) are cardiovascular conditions significant in contemporary practice. In both, the use of anticoagulation with vitamin K antagonists (VKAs) has been traditionally used to prevent adverse events ...
A.J. Camm, A.T. Cohen, Ageno, Agnelli, Alings, Ansell, Ansell, Apostolakis, Avgil-Tsadok, Beyer-Westendorf, Beyer-Westendorf, Beyer-Westendorf, Bohula, Bouillon, Brunner-Ziegler, Caldeira, Caldeira, Camm, Cannon, Cohen, Cohen, Coleman, Connolly, Connolly, Connolly, Cronin-Fenton, De Caterina, De Caterina, De Caterina, De Caterina, Diener, Diener, Diener, Douketis, Easton, Eikelboom, Ensor, F. Verheugt, Fang, Fauchier, Forslund, Fox, Friberg, Friberg, Furugohri, G. Agnelli, G.Y. Lip, Gage, Gibson, Giugliano, Glund, Granger, Gross, Guo, H. Heidbuchel, Hankey, Heidbuchel, Heidbuchel, Heit, Heit, Hijazi, Hohnloser, Husted, Investigators, J.L. Zamorano, Kearon, Keeling, Khorana, Kirchhof, Kooiman, Kooistra, Larsen, Levy, Lip, Lip, Lip, Lip, Lip, Lublóy, Martinez, Masjuan, Mendell, Mendell, Miyasaka, Moore, Morgan, Mungall, Murphy, Márquez-Contreras, Nielsen, Oldgren, Paciaroni, Paciaroni, Patel, Perzborn, Peterson, Pinto, Pollack, Pollack, Price, Prins, Proietti, Proietti, R. De Caterina, Raskob, Renda, Roffi, Roldán, Ruff, Ruff, Sandén, Sardar, Sardar, Sarich, Schulman, Schulman, Senoo, Senoo, Shekelle, Sjögren, Song, Stacy, Stampfuss, Stangier, Steinberg, Tafur, The EINSTEIN investigators, The EINSTEIN–PE Investigators, van der Hulle, van Walraven, Verhamme, Vrijens, Watanabe, Weitz, Wolf, Zamorano   +135 more
core   +5 more sources

A Renal Function Based Trade-Off Analysis of Non-vitamin K Antagonist Oral Anticoagulants in Nonvalvular Atrial Fibrillation

Frontiers in Physiology, 2018
Background: Non-vitamin K antagonist oral anticoagulants (NOACs) depend on some degree of renal excretion, and no head-to-head comparisons based on renal function is available. This study mainly investigated the trade-off property of NOACs in nonvalvular
Ling-Yun Zhou, Shuo-Fei Yang, Zhen Zhang, Chi Zhang, Long Shen, Zhi-Chun Gu, Xiao-Cong Zuo   +6 more
doaj   +1 more source

Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation

Clinical and Applied Thrombosis/Hemostasis, 2020
Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use. As the main adverse event is bleeding, it is relevant whether edoxaban has additional effects on platelet function. We aimed to assess
Juraj Sokol MD, PhD, Frantisek Nehaj MD, Jela Ivankova RNDr, Michal Mokan MD, PhD, Lenka Lisa MD, PhD, Jana Zolkova RNDr, Lubica Vadelova RNDr, Marian Mokan Prof, MD, DSc, FRCP Edin, Jan Stasko Prof, MD, PhD   +8 more
doaj   +1 more source

Electronic monitoring of adherence to once‐daily and twice‐daily direct oral anticoagulants in patients with atrial fibrillation: Baseline data from the SMAAP‐AF trial

Journal of Arrhythmia, 2021
Background Nonadherence diminishes the efficacy of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (NVAF). This report presents the baseline survey results regarding medication adherence among NVAF patients who were ...
Tsuyoshi Shiga, Toshimi Kimura, Noritoshi Fukushima, Yuji Yoshiyama, Kazunori Iwade, Fumiaki Mori, Yoichi Ajiro, Shoji Haruta, Yuichiro Yamada, Emi Sawada, Nobuhisa Hagiwara, the SMAAP‐AF investigators   +11 more
doaj   +1 more source

Pleiotropic effects of NOACs with focus on edoxaban: scientific findings and potential clinical implications

Herzschrittmachertherapie & Elektrophysiologie, 2023
Nicht-Vitamin-K-antagonistische orale Antikoagulanzien (NOAK) sind als Inhibitoren von Faktor Xa (FXa) und Thrombin in der Behandlung und Prävention von Thrombosen etabliert.
A. Goette, M. Mollenhauer, Volker Rudolph, M. Lamparter, Martin Meier, M. Böhm   +5 more
semanticscholar   +1 more source

Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. [PDF]

, 2017
Nonvalvular atrial fibrillation (AF) is a risk factor for stroke in elderly patients. Although warfarin has been used to prevent AF-associated stroke for more than 50 years, non-vitamin K antagonist oral anticoagulants (NOACs) including dabigatran ...
Alexander, Ansell, Bathala, Camm, Connolly, Connolly, Eriksson, Giugliano, Goto, Granger, Harder, Heidbuchel, Hori, Hori, JCS Joint Working Group, Kimura, Matsushima, Mega, Mendell, Ogata, Ogawa, Oldgren, Oldgren, Patel, Sardar, Savelieva, Shen, Tanahashi, Tanigawa, Wong   +29 more
core   +1 more source

Pharmacokinetics of Edoxaban 15 mg in Very Elderly Patients with Nonvalvular Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Study

Thrombosis and Haemostasis, 2023
Background  We evaluated the pharmacokinetics (PK) of low-dose (15 mg) edoxaban in very elderly patients (≥80 years) with nonvalvular atrial fibrillation (NVAF) and high bleeding risk.
T. Yamashita, Yoshiyuki Igawa, Masayuki Fukuzawa, Takuya Hayashi, Stefanie Hennig, K. Okumura   +5 more
semanticscholar   +1 more source